Animal Study Suggests Acetaminophen May Protect Against Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

SAN FRANCISCO-Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

SAN FRANCISCO—Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

In the study, presented at the American Association for Cancer Research (AACR) annual meeting, rats were given low or high doses of 3,2´dimethyl-4-aminobiphenyl (DMAB), a chemical that mimics suspected human colon carcinogens (heterocyclic amines formed during cooking of protein), and acetaminophen or no acetaminophen.

In the animals given carcinogen alone, cellular changes that are common precursors to colon cancer were seen, in relationship to the dose. When the carcinogen was given after acetaminophen, the animals had significantly less cellular evidence of disease, especially gland cell hypertrophy and karyomegaly.

“In our study, even low levels of acetaminophen showed a powerful protective effect in colon cells exposed to DMAB,” said Gary M. Williams, MD, professor of pathology, New York Medical College, at an AACR poster session. “We noted these effects even in animals exposed to much higher doses of DMAB than a human would ever encounter.”

The study was funded in part by a research grant from McNeil Consumer Healthcare.

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content